Klonale Hämatopoese – Verbindungsglied kardiovaskulärer und hämatologischer Erkrankungen

Klonale Hämatopoese ist ein prämaligner Zustand der Blutzellen, der insbesondere in der älteren Bevölkerung sehr häufig ist. Er geht nicht nur mit einem erhöhten Risiko für hämatologische Erkrankungen einher, sondern ist insbesondere aufgrund des vermehrten Vorkommens von kardiovaskulären Erkrankungen klinisch hochrelevant. Auch im Kontext allogener hämatopoetischer Stammzelltransplantationen spielt klonale Hämatopoese eine zunehmend wichtige Rolle.

Abstract

Clonal hematopoiesis is an acquired premalignant condition of blood cells. It is very frequent in the elderly population and is associated with an increased risk of hematologic disorders and cardiovascular diseases. Likewise, clonal hematopoiesis plays a critical role in the development of therapy-related myeloid neoplasms. In case of donor clonal hematopoiesis, transplantation outcome differs in various parameters compared to transplantations with donors who do not have clonal hematopoiesis. Finally, donor cell leukemia is a rare but devastating complication of allogeneic transplantation that is more frequent in specific constellations of donor clonal hematopoiesis.

Schlüsselwörter

klonale Hämatopoese - hämatopoetische Stammzelle - Mutation - Chemotherapie - hämatopoetische Stammzelltransplantation

Key words

clonal hematopoiesis - hematopoietic stem cell - mutation - chemotherapy - hematopoietic stem cell transplantation

Publication History

Article published online:
11 August 2022

• Literatur

• 1 Jaiswal S, Fontanillas P, Flannick J. et al. Age-related clonal hematopoiesis associated with adverse outcomes. NEJM 2014; 371: 2488-2498 DOI: 10.1056/NEJMoa1408617.
• 2 Genovese G, Kähler AK, Handsaker RE. et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. NEJM 2014; 371: 2477-2487 DOI: 10.1056/NEJMoa1409405.
• 3 Xie M, Lu C, Wang J. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Med 2014; 20: 1472-1478 DOI: 10.1038/nm.3733.
• 4 Arends CM, Galan-Sousa J, Hoyer K. et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia 2018; 32: 1908-1919 DOI: 10.1038/s41375–018–0047–7.
• 5 Coombs CC, Zehir A, Devlin SM. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 2017; 21: 374-382.e374 DOI: 10.1016/j.stem.2017.07.010.
• 6 Steensma DP, Bejar R, Jaiswal S. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126: 9-16 DOI: 10.1182/blood-2015–03–631747.
• 7 Shlush LI. Age-related clonal hematopoiesis. Blood 2018; 131: 496-504 DOI: 10.1182/blood-2017–07–746453.
• 8 Challen GA, Sun D, Jeong M. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genet 2011; 44: 23-31 DOI: 10.1038/ng.1009.
• 9 Moran-Crusio K, Reavie L, Shih A. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24 DOI: 10.1016/j.ccr.2011.06.001.
• 10 Abdel-Wahab O, Gao J, Adli M. et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. Journal of Experimental Medicine 2013; 210: 2641-2659 DOI: 10.1084/jem.20131141.
• 11 Jaiswal S, Natarajan P, Silver AJ. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. NEJM 2017; 377: 111-121 DOI: 10.1056/NEJMoa1701719.
• 12 Fuster JJ, MacLauchlan S, Zuriaga MA. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017; 355: 842-847 DOI: 10.1126/science.aag1381.
• 13 Sano S, Oshima K, Wang Y. et al. CRISPR-Mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circul Res 2018; 123: 335-341 DOI: 10.1161/CIRCRESAHA.118.313225.
• 14 SanMiguel JM, Young K, Trowbridge JJ. Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis. Experimental Hematology 2020; DOI: 10.1016/j.exphem.2020.09.197.. doi: 10.1016/j.exphem.2020.09.197
• 15 Bouzid H, Belk JA, Jan M. et al. Clonal hematopoiesis is associated with protection from Alzheimer’s disease. medRxiv 2021; DOI: 10.1101/2021.12.10.21267552.
• 16 Abelson S, Collord G, Ng SWK. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 2018; 559: 400-404 DOI: 10.1038/s41586–018–0317–6.
• 17 Desai P, Mencia-Trinchant N, Savenkov O. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature Med 2018; 24: 1015-1023 DOI: 10.1038/s41591–018–0081-z.
• 18 Yoshizato T, Dumitriu B, Hosokawa K. et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. NEJM 2015; 373: 35-47 DOI: 10.1056/NEJMoa1414799.
• 19 Zhang CRC, Nix D, Gregory M. et al. Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. Exp Hematol 2019; 80: 36-41.e33 DOI: 10.1016/j.exphem.2019.11.008.
• 20 Arends CM, Weiss M, Christen F. et al. Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Haematologica 2020; 105: e264-e267 DOI: 10.3324/haematol.2019.223305.
• 21 Kim PG, Niroula A, Shkolnik V. et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med 2021; 218 DOI: 10.1084/jem.20211872.
• 22 Miller PG, Qiao D, Rojas-Quintero J. et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood 2022; 139: 357-368 DOI: 10.1182/blood.2021013531.
• 23 Vlasschaert C, McNaughton AJM, Chong M. et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 2022; 33: 985-995 DOI: 10.1681/asn.2021060774.
• 24 Thakkar JP, McCarthy BJ, Villano JL. Age-specific cancer incidence rates increase through the oldest age groups. The American Journal of the Medical Sciences 2014; 348: 65-70 DOI: 10.1097/maj.0000000000000281.
• 25 McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 2017; 17: 513-527 DOI: 10.1038/nrc.2017.60.
• 26 Bolton KL, Ptashkin RN, Gao T. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics 2020; 52: 1219-1226 DOI: 10.1038/s41588–020–00710–0.
• 27 Arends CM, Dimitriou S, Stahler A. et al. Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. Blood 2022; 139: 1593-1597 DOI: 10.1182/blood.2021014108.
• 28 Ortmann CA, Dorsheimer L, Abou-El-Ardat K. et al. Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation. Cell Reports 2019; 27: 2022-2028.e2023 DOI: 10.1016/j.celrep.2019.04.064.
• 29 Gibson CJ, Lindsley RC, Tchekmedyian V. et al. Clonal Hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol 2017; 35: 1598-1605 DOI: 10.1200/jco.2016.71.6712.
• 30 Husby S, Favero F, Nielsen C. et al. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia 2020; 34: 3256-3268 DOI: 10.1038/s41375–020–0795-z.
• 31 Mouhieddine TH, Sperling AS, Redd R. et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Commun 2020; 11: 2996 DOI: 10.1038/s41467–020–16805–5.
• 32 Frick M, Chan W, Arends CM. et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2019; 37: 375-385 DOI: 10.1200/jco.2018.79.2184.
• 33 Gibson CJ, Kim HT, Zhao L. et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol 2022; 40: 189-201 DOI: 10.1200/jco.21.02286.
• 34 Oran B, Champlin RE, Wang F. et al. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 2022; 36: 257-262 DOI: 10.1038/s41375–021–01312–3.
• 35 Gondek LP, Zheng G, Ghiaur G. et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia 2016; 30: 1916-1920 DOI: 10.1038/leu.2016.63.
• 36 Svensson EC, Madar A, Campbell CD. et al. TET2-Driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol 2022; DOI: 10.1001/jamacardio.2022.0386.